NSP...FDA warning is not good..with Colorectal cancer usually being terminal, the uptake of this drug may not all that's touted. I sold at loss today
o study Gattex’s long-term safety, the FDA is requiring a postmarket study of SBS patients treated with the drug in a routine clinical setting to further evaluate the drug’s potential increased risk to cause colorectal cancer and other conditions. Patients in this study will be followed for at least 10 years.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.